VOLITIONRX LTD — Major Shareholding Notification 2020

Jun 10, 2020

SC 13D/A 1 ea122884-13da3eight_volition.htm AMENDMENT NO. 3 TO SCHEDULE 13D

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

VolitionRx Limited

Field: Rule-Page

Field: /Rule-Page

(Name of Company)

Common Stock, $0.001 par value per share

Field: Rule-Page

Field: /Rule-Page

(Title of Class of Securities)

928661107

Field: Rule-Page

Field: /Rule-Page

(CUSIP Number)

Eight Corporation Limited

c/o Crowe Morgan Management Limited

8 St. George’s Street

Douglas, Isle of Man IM1 1AH

+1 44 1624 665 1000

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

June 8, 2020

Field: Rule-Page

Field: /Rule-Page

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

• The remainder of this cover page shall be filled out for a person’s initial filing on this form with respect to subject class of securities, and for any subsequent amendment containing information which would alter disclosures in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

1.	NAMES OF REPORTING PERSON
	EIGHT CORPORATION LIMITED
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(SEE INSTRUCTIONS)
	(a) ☐
	(b) ☒
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions)
	WC, OO
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) (see instructions) ☐
6.	CITIZENSHIP OR PLACE OF ORGANIZATION
	ISLE OF MAN

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	SOLE VOTING POWER
	0
8.	SHARED VOTING POWER
	12,045,332
(1)
9.	SOLE DISPOSITIVE POWER
	0
10.	SHARED DISPOSITIVE POWER
	12,045,332
(1)

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	12,045,332 (1)
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
	(see instructions) ☐
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	23.8% (2)
14.	TYPE OF REPORTING PERSON (see instructions)
	HC

(1) Includes (i) 11,706,913 shares of VolitionRx Limited, or Issuer, common stock, par value $0.001 per share held by Cotterford Company Limited, or Cotterford, and (ii) 338,419 shares of Issuer common stock held by Hever Investments Limited, or Hever, a company organized in the Isle of Man. Eight Corporation Limited is the sole corporate director of Cotterford and the sole corporate director of Hever.

(2) Based on 50,591,382 issued and outstanding shares of Issuer common stock as of May 22, 2020, as reported in the Issuer’s Prospectus Supplement filed with the SEC on May 21, 2020, (File No. 333-227248) (the “Prospectus), which includes both the shares offered under that Prospectus and the underwriters’ option.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

1.	NAMES OF REPORTING PERSON
	COTTERFORD COMPANY LIMITED
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(SEE INSTRUCTIONS)
	(a) ☐
	(b) ☒
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions)
	WC, OO
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) (see instructions) ☐
6.	CITIZENSHIP OR PLACE OF ORGANIZATION
	ISLE OF MAN

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	SOLE VOTING POWER
	0
8.	SHARED VOTING POWER
	11,706,913
9.	SOLE DISPOSITIVE POWER
	0
10.	SHARED DISPOSITIVE POWER
	11,706,913

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	11,706,913
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
	(see instructions) ☐
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	23.1% (1)
14.	TYPE OF REPORTING PERSON (see instructions)
	IV

(1) Based on 50,591,382 issued and outstanding shares of Issuer common stock as of May 22, 2020, as reported in the Prospectus, which includes both the shares offered under that Prospectus and the underwriters’ option.

Field: Page; Sequence: 3; Value: 2

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page

This amendment No. 3 to Schedule 13D (this “ Amendment No. 3 ”), amends and supplements the Schedule 13D filed on May 5, 2020, as amended, (the “ Initial 13D ”) by the Reporting Persons, relating to the common stock, par value $0.001 per share (the “ Common Stock ”), of VolitionRx Limited, a Delaware corporation (the “ Issuer ”). Capitalized terms not defined in this Amendment No. 3 shall have the meanings ascribed to them in the Initial 13D.

The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. Except as specifically amended by this Amendment No. 3, the Initial 13D is unchanged.

Item 4. Purpose of Transaction

Item 4 of the Initial 13D is hereby amended and supplemented by the addition of the following:

“On June 8, 2020, certain of the Reporting Persons sent a letter to the board of directors of the Issuer relating to, among other things, the appointment of three directors selected by the Reporting Persons and the immediate replacement of the Issuer’s CEO.”

Item 7. Material to be Filed as Exhibits

Exhibit 1 Joint Filing Agreement, effective July 29, 2019, by and between Cotterford Company Limited and Eight Corporation Limited.*

• Previously filed

Field: Page; Sequence: 4; Value: 2

Field: Sequence; Type: Arabic; Name: PageNo 4 Field: /Sequence

Field: /Page

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 10, 2020	EIGHT CORPORATION LIMITED
	By:	/s/ Amy Slee
		Amy Slee, Director
Dated: June 10, 2020	COTTERFORD COMPANY LIMITED
	By:	EIGHT CORPORATION LIMITED, as Director
	By:	/s/ Amy Slee
		Amy Slee, Director

5

Field: Rule-Page

Field: /Rule-Page